RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)

Clinical trials for RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) trials appear

Sign up with your email to follow new studies for RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New 'Living Drug' trial targets Tough-to-Treat lymphoma

Disease control Ongoing

This study is testing an experimental cell therapy called TAK-007 in adults whose B-cell non-Hodgkin lymphoma has returned or not responded to prior treatments. Participants receive chemotherapy followed by an infusion of specially engineered immune cells designed to find and att…

Matched conditions: RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)

Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)

Get alerted when new RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) trials appear

New 'Living Drug' trial targets Tough-to-Treat lymphoma